<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141009019470N105</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-25</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The comparison between oral modafinil and placebo to accelerate the rate of improvement in the level of consciousness in adult patients with moderate or severe acute traumatic brain injury admitted in intensive care units of Rajaee Trauma Center in 1399-1400</public_title>
      <acronym></acronym>
      <scientific_title>The comparison between oral modafinil and placebo to accelerate the rate of improvement in the level of consciousness in adult patients with moderate or severe acute traumatic brain injury admitted in intensive care units of Rajaee Trauma Center in 1399-1400</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-02-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>314</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53612</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly divided into two groups of drugs and placebo. Randomization by block randomization method in 4.6.8 blocks and using random numbers taken from the site https://www.sealedenvelope.com.
A person who examines patients for inclusion is unaware of the random patient allocation table. Information about each patient is collected from the time of the examination in terms of enrollment conditions until each of the following outcomes is reached: The end of the follow-up period or death or withdrawal from the study, whichever occurs sooner, will be recorded and reported, Blinding description: The patient and the person measuring and determining the outcomes do not know which group of drugs or placebos the patient is in.
In order not to inform patients, physicians, nurses and the entire treatment team about assigning patients to two groups, placebos are prepared with the help of the pharmacosynthetic department of the School of Pharmacy in a completely similar way in terms of color, size and weight.
People in the drug group are given 200 mg of oral modafinil (Torrent Pharma, UK) daily, dissolved in 10 cc of plain water, at 9 a.m. through a tube in the stomach for one week. .
Patients' GCS (Glasgow Coma Score) score is recorded every 8 hours. (The highest GCS score is recorded within 8 hours.).</study_design>
      <phase>2-3</phase>
      <hc_freetext>Brain injury.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in the drug group receive 200 mg of oral modafinil daily (Torrent Pharma, UK) dissolved in 10 cc of plain water at 9 am through a tube placed in the stomach. Intervention 2: Control group: In order not to inform patients, physicians, nurses and the entire treatment team about assigning patients to two groups, placebo is prepared with the help of the pharmacosynthetic department of the School of Pharmacy in a completely similar way in terms of color, size and weight. The placebo is dissolved in 10 cc of plain water and patients receive the placebo at 9 am through a tube inserted into the stomach.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is It is against the policies of our center.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Zand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Faghihi Hospital, Zand Street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134844119</zip>
        <telephone>+98 71 3647 4270</telephone>
        <email>zandfarid@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farid Zand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Faghihi Hospital, Zand Street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134844119</zip>
        <telephone>+98 71 3647 4270</telephone>
        <email>zandfarid@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who have a GCS score between 6 and 12 at the time of initiation of NG tube feeding in the ICU
Head AIS score above 3 on the first day of ICU stay, the AIS score of the other parts  below 3 on the first day of  ICU stay, the consent of the patient's guardian or legal guardian
Consent of the patient's guardian or legal guardian
Age over 18 years and under 70 years
Patients with moderate or severe head injury who are admitted to intensive care</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe side effects such as severe agitation or anaphylactic reaction to modafinil
Occurrence of seizures
Incidence of death or brain death
multiple trauma
Injury Severity Score less than 20
History of psychotropic and brain stimulant drug abuse and alcoholism
History of severe liver failure
History of seizures
History of Anxiety Disorders
Cardiac or respiratory recurrence in the first 6 days of hospitalization</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S06.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diffuse traumatic brain injury</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in the drug group receive 200 mg of oral modafinil daily (Torrent Pharma, UK) dissolved in 10 cc of plain water at 9 am through a tube placed in the stomach</i_keyword>
      <i_keyword>Control group: In order not to inform patients, physicians, nurses and the entire treatment team about assigning patients to two groups, placebo is prepared with the help of the pharmacosynthetic department of the School of Pharmacy in a completely similar way in terms of color, size and weight. The placebo is dissolved in 10 cc of plain water and patients receive the placebo at 9 am through a tube inserted into the stomach.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Unawareness condition. Timepoint: At intervals of one, three and six months after discharge from the hospital. Method of measurement: GOS-E (Glasgow Outcome Scale-Extended).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Agitation. Timepoint: Every 4 hour. Method of measurement: RASS (Richmond Agitation-Sedation Scale).</sec_outcome>
      <sec_outcome>Level of Conciseness. Timepoint: Every 8 hours. Method of measurement: GCS(Glasgow Coma Score).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-06</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor of research, Shiraz University of Medical Sciences, 7th floor, central building of Shiraz University of Medical Sciences, Zand street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
